EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma

Rodrigo Entrialgo-Cadierno, Konstantina Morali, Iker Feliu, Yingyun Wang, James W Evans, Mariana Yañez-Bartolome, Ines Lopez, Irati Macaya, Cristina Cueto-Ureña, Daniel Sin-Coscujuela, Yaiza Senent, Jose M Herranz und 18 weitere

Cancer Cell · 2026-06 · 44 (6) · 1218-1234.e7

DOI: 10.1016/j.ccell.2026.03.020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2026-06. Verfasst von Rodrigo Entrialgo-Cadierno und 29 weiteren Autor:innen. Beteiligte Einrichtung: Program in Solid Tumors, Center for Applied Medical Research (CIMA)-University of Navarra, 31008 Pamplona, Navarra, Spain. Electronic address: rodrig…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Proto-Oncogene Proteins p21(ras), Guanosine Triphosphate. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia, Innovación y Universidades, Revolution Medicines, Government of Spain Ministry of Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

About 25% of cholangiocarcinoma (CCA) tumors harbor KRAS mutations. Here, we investigated the activity of RAS(ON) multi-selective inhibitors, which target the active, GTP-bound state of mutant and wild-type variants of canonical RAS isoforms, in preclinical models and in patients with KRAS mutant CCA. RAS(ON) multi-selective inhibitors yield strong anticancer responses in cell- and patient-derived xenografts and immunocompetent allograft models. Consistent with these preclinical findings, we describe clinical activity of the RAS(ON) multi-selective inhibitor daraxonrasib in two patients with advanced KRAS G12 CCA. RAS-GTP inhibition also potentiates the activity of current standard-of-care CCA regimens to prolong survival in cell-derived human xenografts and mouse allografts. Furthermore, we demonstrate that intrinsic and acquired resistance to RAS(ON) multi-selective inhibitors mainly rely on mechanisms that drive RAS signaling overactivation. Overall, our findings indicate that KRAS mutant CCA is addicted to RAS signaling for proliferation and support the potential clinical evaluation of RAS-GTP inhibition in CCA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaBile Duct NeoplasmsProto-Oncogene Proteins p21(ras)Guanosine TriphosphateAntineoplastic AgentsHumansAnimalsMiceXenograft Model Antitumor AssaysMutationSignal TransductionCell Line, TumorCell ProliferationFemaleMaleDrug Resistance, NeoplasmAcetonitrilesPiperazinesPyrimidines

Stichwörter der Autor:innen

KRAS oncogeneRAS(ON) multi-selective inhibitorbiliary tract cancercholangiocarcinomadrug combinationspreclinical modelstargeted therapytherapy resistance

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanGuanosine TriphosphateadagrasibAntineoplastic AgentsAcetonitrilesPiperazinesPyrimidines

Autor:innen und Institutionen

  • Program in Solid Tumors, Center for Applied Medical Research (CIMA)-University of Navarra, 31008 Pamplona, Navarra, Spain. Electronic address: rodrigo.entrialgo@gmail.com.
  • Program in Solid Tumors, Center for Applied Medical Research (CIMA)-University of Navarra, 31008 Pamplona, Navarra, Spain.
  • Revolution Medicines, Redwood City, CA 94063, USA.
  • Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain; Translational Oncol…
  • HepatoBiliary Tumours Lab, Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, 37007 Salamanca, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas (CIBEREH), 28029 Madrid, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas (CIBEREH), 28029 Madrid, Spain; Department of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute, Donostia University Hospital,…

Förderung

  • Ministerio de Ciencia, Innovación y Universidades
  • Revolution Medicines
  • Government of Spain Ministry of Universities
  • European Regional Development Fund
  • Albert Einstein Cancer Center
  • Agencia Estatal de Investigación

Zitieren

APA

Entrialgo-Cadierno, R., Morali, K., Feliu, I., Wang, Y., Evans, J. W., Yañez-Bartolome, M., Lopez, I., Macaya, I., Cueto-Ureña, C., Sin-Coscujuela, D., Senent, Y., Herranz, J. M., Raghulan, R., Vaquero, J., Banales, J. M., Macarulla, T., Ponz-Sarvise, M., Pechuan-Jorge, X., Guruceaga, E., …, & Vicent, S. (2026). Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma. Cancer Cell, 44(6), 1218-1234.e7. https://doi.org/10.1016/j.ccell.2026.03.020

Vancouver

Entrialgo-Cadierno R, Morali K, Feliu I, Wang Y, Evans JW, Yañez-Bartolome M, et al. Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma. Cancer Cell. 2026;44(6):1218-1234.e7. doi:10.1016/j.ccell.2026.03.020

BibTeX
@article{EntrialgoCadierno2026,
  author = {Entrialgo-Cadierno, Rodrigo and Morali, Konstantina and Feliu, Iker and Wang, Yingyun and Evans, James W and Yañez-Bartolome, Mariana and Lopez, Ines and Macaya, Irati and Cueto-Ureña, Cristina and Sin-Coscujuela, Daniel and Senent, Yaiza and Herranz, Jose M and Raghulan, Rashi and Vaquero, Javier and Banales, Jesus M and Macarulla, Teresa and Ponz-Sarvise, Mariano and Pechuan-Jorge, Ximo and Guruceaga, Elisabeth and Schumpp, Alyssa and Garcia, Alia V and Kim, Alyssa and Herzberg, Benjamin O and Azad, Nilofer and Hegde, Aparna and Tian, Tian V and Aronchik, Ida and Singh, Mallika and Jiang, Jingjing and Vicent, Silve},
  title = {Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma},
  journal = {Cancer Cell},
  year = {2026},
  volume = {44},
  number = {6},
  pages = {1218--1234.e7},
  doi = {10.1016/j.ccell.2026.03.020}
}
Kostenlos starten →